Systemic Anti-Cancer Therapy Regimen Library
Leukaemias Regimens
Haematology regimens within the SACT Regimen Library currently only specify mandatory supportive care medicines to be used for all patients, unless contraindicated. A clinically equivalent mandatory medicine may be substituted as per institutional practice.
Supportive care factors are included in all regimens, with the appropriate dimensions (value) as Recommended (for most patients), Consider (for some patients after clinical risk assessment), or with guidance (e.g. emetogenicity classification or if variable). Centres are expected to include antiemetics and other supportive care medicines within their own prescribing systems.
Acute lymphoblastic Regimens
Published
Name
|
Version
|
Date
|
|---|---|---|
| LEU ALL precursor B-cell - AALL1131 [very high risk] | 2.0.0 | 06/12/2024 |
| LEU ALL precursor B-cell - blinatumomab [CNS1 and CNS2] | 1.0.0 | 18/03/2024 |
| LEU ALL precursor B-cell - blinatumomab [CNS3] | 1.0.0 | 18/03/2024 |
UKALL14 Regimens
Published
HyperCVAD Regimens
Published
UKALL60+ Regimens
Published
|
Name
|
Version
|
Date
|
|---|---|---|
| LEU ALL - UKALL60+ [non-intensive] | 1.0.0 | 09/11/2023 |
| LEU ALL BCR-ABL1+ - UKALL60+ with daSATinib | 1.0.0 | 09/11/2023 |
| LEU ALL BCR-ABL1+ - UKALL60+ with imatinib | 1.0.0 | 09/11/2023 |
AALL1131 Regimens
Published
| Name | Version | Date |
|---|---|---|
| LEU ALL precursor B-cell - AALL1131 [very high risk] | 1.0.0 | 17/06/2024 |
GMALL Regimens
Published
|
Name
|
Version
|
Date
|
|---|---|---|
| LEU ALL precursor T-cell - GMALL T-LBL 1/2004 [55 years and under] | 1.0.0 | 20/05/2024 |
| LEU ALL precursor T-cell - GMALL T-LBL 1/2004 [over 55 years] | 1.0.0 | 20/05/2024 |
Acute myeloid Regimens
Published
Acute promyelocytic Regimens
Published
Chronic lymphocytic Regimens
Published
|
Name
|
Version
|
Date
|
|---|---|---|
| LEU CLL - acalabrutinib | 1.0.0 | 19/09/2023 |
| LEU CLL - chlorambucil | 1.0.0 | 15/12/2022 |
| LEU CLL - chlorambucil [flat dosing] | 1.0.0 | 15/12/2022 |
| LEU CLL - chlorambucil and oBINUTUZumab | 1.0.0 | 19/09/2023 |
| LEU CLL - FCR [fludarabine, CYCLOPHOSPHamide and RITUximab] [oral] [3 day] | 1.0.0 | 21/07/2023 |
| LEU CLL - FCR [fludarabine, CYCLOPHOSPHamide and RITUximab] [oral] [5 day] | 1.0.0 | 21/07/2023 |
| LEU CLL - FCR [IV] fludarabine, CYCLOPHOSPHamide and RITUximab | 1.0.0 | 21/07/2023 |
| LEU CLL - ibrutinib | 1.0.0 | 19/09/2023 |
| LEU CLL - RITUximab and bendamustine | 1.0.0 | 21/12/2023 |
| LEU CLL - venetoclax | 1.0.0 | 21/07/2023 |
| LEU CLL - venetoclax and oBINUTUZumab | 1.0.0 | 21/12/2023 |
| LEU CLL - venetoclax and RITUximab | 1.0.0 | 30/11/2023 |
| LEU CLL Relapsed - aLEMTUzumab [IV] | 1.0.0 | 21/12/2023 |
| LEU CLL Relapsed - aLEMTUzumab [subcut] | 1.0.0 | 24/12/2023 |
Chronic myeloid Regimens
Published
|
Name
|
Version
|
Date
|
|---|---|---|
| LEU CML - daSATinib | 1.0.0 | 21/07/2023 |
| LEU CML - imatinib | 1.0.0 | 30/11/2023 |
| LEU CML - nilotinib | 1.0.0 | 25/05/2023 |
| LEU CML - pONATinib | 1.0.0 | 04/08/2023 |
Chronic myelomonocytic Regimens
Published
| Name | Version | Date |
|---|---|---|
| LEU CMML - azacitidine [7 day] | 1.0.0 | 28/03/2023 |
Hairy cell Regimens
Published
|
Name
|
Version
|
Date
|
|---|---|---|
| LEU HCL - cladribine | 1.0.0 | 21/07/2023 |
| LEU HCL - cladribine and RITUximab | 1.0.0 | 28/01/2024 |
| LEU HCL - RITUximab | 1.0.0 | 19/09/2023 |
Myelodysplastic syndrome Regimens
Published
|
Name
|
Version
|
Date
|
|---|---|---|
| Myelodysplastic syndrome - azacitidine [5 day] | 1.0.0 | 28/03/2023 |
| Myelodysplastic syndrome - azacitidine [7 day] | 1.0.0 | 28/03/2023 |
Myeloproliferative neoplasm Regimens
Published
|
Name
|
Version
|
Date
|
|---|---|---|
| MPN - busulfan | 1.0.0 | 21/12/2022 |
| MPN Myelofibrosis - ruxolitinib | 1.0.0 | 23/07/2023 |
T-cell prolymphocytic Regimens
Published
|
Name
|
Version
|
Date
|
|---|---|---|
| LEU T-PLL - aLEMTUzumab [IV] | 2.0.0 | 24/12/2023 |
| LEU T-PLL Relapsed - pentostatin | 1.0.0 | 23/07/2023 |